Copayment of Choline alfoscerate other than dementia is 80%

Report on 'Results of reevaluation of drug benefit adequacy'

Administrative notice and revision work in August

The government's commitment to the re-evaluation of the already listed Choline alfoscerate was clear, and the results of the re-evaluation of Choline alfoscerate, which had strong social demands, eventually ended up maintaining the benefits only for dementia.

 

The government left only the task of applying the revision after making an administrative notice to revise the relevant notice.

 

If it proceeds sequentially, it may be implemented at the end of next month.

 

The MOHW held the 13th general meeting of the Health Insurance Policy Deliberation Committee this afternoon (24th), and proposed and reported the Amendment of the Pharmaceutical reimbursed list and the upper limit table.

 

The Pharmaceutical Benefits Evaluation Committee conducted a deliberation by the Pharmaceuticals Post-Assessment Subcommittee on the 4th of June and the 11th of the Committee, gathered industry opinions such as pharmaceutical companies from the 12th to the 13th of this month, held a round-table meeting with the Pharmaceuticals Association on the 16th In addition to 81 pharmaceutical companies, the Korean Neurological Association, the Korean Neurosurgical Society, and the Pharmaceutical Society for Health Society submitted different opinions surrounding Choline alfoscerate to the HIRA.

 

Pharmaceutical companies generally lowered the copayment for selective benefit from 80% to 50% for brain-related diseases in consideration of social needs ▲submitted severe brain-related disease literature ▲high-priced alternatives had no effect on financial savings ▲Procedure lack of transparency ▲After deriving the results of clinical re-evaluation from the MFDS, it was suggested to adjust insurance benefits.

 

Subsequently, the HIRA hled a subcommittee on the 21st of this month and decided to maintain the re-evaluation and put it up on the 23rd.

 

As a result of the review by the Pharmaceutical Evaluation Committee ▲selective benefit is considered in social needs, but the minimum benefit rate is required because the clinical usefulness is insufficient.

 

▲The submitted documents are already reviewed as data on patients with dementia that may occur due to stroke, etc.

 

Data ▲ Among 5~6 prescriptions for inexpensive alternative drugs ▲Procedures such as public hearings, deliberation and review of health ratings, and opinions from pharmaceutical companies are undergoing legal procedures.

 

The MOHW plans to announce and revise the proposed amendment to 'a partial revision of Criteria for Adjustment and Method on Reimbursed services' during next month as the report of the Deliberation Committee is completed.

 

In this case, it can be applied even at the end of August.

 

Therefore, according to the government's will, it is expected that the reduction of Choline alfoscerate benefit will be implemented in late August or September.

 

On the other hand, the efficacy of this drug is ▲ secondary symptoms due to cerebrovascular defects and deterioration in memory, confusion, and decreased concentration due to degenerative or degenerative cerebral stromal syndrome ▲ emotional and behavioral changes ▲ sensible pseudodepressiveness, for clinical usefulness.

 

The dementia-related disease with evidence (within the efficacy effect) maintains benefit, and other diseases with insufficient evidence are converted into selective benefit (copayment rate: 30→80%) and reevaluate the appropriateness of reimbursed services for selective benefit after 3 years.

 

Choline alfoscerate has a high rate of increase in claims, but there are social controversies over clinical evidence and are sold as health functional foods in major foreign countries.

 

This ingredient, listed in 2007, has 232 items listed as of May this year.

 

In 2016, it was claimed to be ₩167.6 billion, and in 2019, it exploded to ₩352.5 billion.

 

So far, the National Assembly and civic groups have constantly raised concerns about the abuse of this drug and the appropriateness of insurance benefits.